Abstract
Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines identified cellular immunopathology and antibody-dependent enhancement as potential safety issues. We discuss the implications of these findings for COVID-19 vaccine development and our approach to optimizing for safety and efficacy.
All Keywords
【저자키워드】 breath, 【초록키워드】 Efficacy, Vaccine, coronavirus, antibody, SARS-CoV, Antibody-dependent enhancement, immunopathology, severe acute respiratory syndrome Coronavirus, Severe acute respiratory syndrome, respiratory, cellular, acute respiratory syndrome, acute respiratory syndrome coronavirus, COVID-19 vaccine development, potential safety issues, implication, approach, 【제목키워드】 COVID-19 vaccine, immune, janus,
【저자키워드】 breath, 【초록키워드】 Efficacy, Vaccine, coronavirus, antibody, SARS-CoV, Antibody-dependent enhancement, immunopathology, severe acute respiratory syndrome Coronavirus, Severe acute respiratory syndrome, respiratory, cellular, acute respiratory syndrome, acute respiratory syndrome coronavirus, COVID-19 vaccine development, potential safety issues, implication, approach, 【제목키워드】 COVID-19 vaccine, immune, janus,
{{{ 추상적인 }}}
중증급성호흡기증후군 코로나바이러스(SARS-CoV) 백신에 대한 이전 작업은 잠재적인 안전성 문제로 세포 면역병리학과 항체 의존적 강화를 확인했습니다. 우리는 이러한 발견이 COVID-19 백신 개발에 미치는 영향과 안전성 및 효능을 최적화하기 위한 접근 방식에 대해 논의합니다.